SCHEMBL3202267

SCHEMBL3202267

CC(=N)Nc1ccc2oc(-c3ccc(F)cc3F)nc2c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.55
NPC1 O15118 8/20 0.55
KDM4E B2RXH2 8/20 0.55
SMN1; SMN2 Q16637 7/20 0.55
ALDH1A1 P00352 6/20 0.55
HPGD P15428 3/20 0.55
HSD17B10 Q99714 3/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 9/20 0.51
POLB P06746 4/20 0.51
UTRN P46939 1/20 0.49
KDR P35968 2/20 0.48
TP53 P04637 6/20 0.48
RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3194115 0.87 NPC1 (0.68) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3202109 0.84 MAPT (0.67) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3204497 0.81 MAPT (0.65) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3198911 0.80 HDAC6 (0.56) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3183505 0.78 MAPT (0.67) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3204607 0.78 MAPT (0.66) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3203340 0.77 KMT2A (0.56) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3201639 0.77 KDR (0.62) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3196281 0.76 ALDH1A1 (0.76) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3202715 0.76 MAPT (0.54) RAB9AKDM4ESMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1571142-B1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM SPA (IT) 2012-09-12 EP disclosed
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production MAKOVEC FRANCESCO 2010-05-13 US disclosed
US-7674809-B2 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM S.P.A. (IT) 2010-03-09 US disclosed
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM SPA 2005-09-08 US disclosed
EP-1571142-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production Rottapharm S.p.A. (IT) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production NOS3, NOS1, NOS2 RAB9A 2198/4885NPC1 4082/4885KDM4E 3052/4885
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production NOS3, NOS1, NOS2 RAB9A 2198/4885NPC1 4082/4885KDM4E 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.